12<str<strong>on</strong>g>Focused</str<strong>on</strong>g> <strong>on</strong> specialized careti<strong>on</strong> center, and an apheresis collecti<strong>on</strong> center. <strong>Baylor</strong> Dallas is <strong>on</strong>e of <strong>on</strong>ly eight programsnati<strong>on</strong>wide to offer all four of <strong>the</strong>se comp<strong>on</strong>ents.Each year, <strong>on</strong> <strong>the</strong> anniversary of <strong>the</strong>ir initial accreditati<strong>on</strong> membership, all NMDP networkcenters are reviewed to ensure <strong>the</strong>ir c<strong>on</strong>tinued compliance with membership standards.The transplant center is reviewed based up<strong>on</strong> criteria adopted by <strong>the</strong> NMDP to ensure tha<strong>the</strong>matopoietic stem cells from unrelated d<strong>on</strong>ors will be transplanted at instituti<strong>on</strong>s experiencedin allogeneic stem cell transplantati<strong>on</strong>. D<strong>on</strong>or centers are held to guidelines establishedto ensure that unrelated marrow d<strong>on</strong>ors are medically eligible and informed about <strong>the</strong>hematopoietic stem cell d<strong>on</strong>ati<strong>on</strong> process and to safeguard <strong>the</strong> d<strong>on</strong>or’s health and c<strong>on</strong>fidentiality.Apheresis and b<strong>on</strong>e marrow collecti<strong>on</strong> centers must c<strong>on</strong>tinuously meet standardsthat promote d<strong>on</strong>or safety and product quality to include collecti<strong>on</strong>, testing, labeling, andtransportati<strong>on</strong> of <strong>the</strong> product. In 2007, our program was again accredited in all four areas;<strong>the</strong> program has been c<strong>on</strong>tinuously accredited since 1984.To assess <strong>the</strong>se <strong>patient</strong>s’complex needs and help<strong>the</strong>m develop a higherlevel of functi<strong>on</strong>, avariety of professi<strong>on</strong>alsare involved, includingsocial workers, physical<strong>the</strong>rapists, occupati<strong>on</strong>al<strong>the</strong>rapists, and dietitians.Graft-Versus-Host Disease ClinicThe Graft-Versus-Host Disease (GVHD) Clinic at <strong>Baylor</strong> Samm<strong>on</strong>s Cancer Center helps<strong>patient</strong>s with serious physical complicati<strong>on</strong>s and psychosocial issues resulting from GVHD.This multidisciplinary clinic is held m<strong>on</strong>thly in <strong>the</strong> out<strong>patient</strong> B<strong>on</strong>e Marrow Transplant Clinic.Chr<strong>on</strong>ic GVHD usually develops at least 3 m<strong>on</strong>ths after transplant and c<strong>on</strong>sists of a reacti<strong>on</strong>between <strong>the</strong> immunological cells (those transplanted from <strong>the</strong> d<strong>on</strong>or) and recipient cells(those from <strong>the</strong> individual receiving <strong>the</strong> transplant). The reacti<strong>on</strong> is most comm<strong>on</strong>ly seen in<strong>the</strong> liver, gastrointestinal tract, and skin. Many <strong>patient</strong>s experience significant disabling anddisfiguring physical changes from chr<strong>on</strong>ic GVHD, which can lead to loss of functi<strong>on</strong>, poorbody image, and lack of self-esteem.To assess <strong>the</strong>se <strong>patient</strong>s’ complex needs and help <strong>the</strong>m develop a higher level of functi<strong>on</strong>,a variety of professi<strong>on</strong>als are involved, including social workers, physical <strong>the</strong>rapists, occupati<strong>on</strong>al<strong>the</strong>rapists, and dietitians. The clinic staff is highly specialized and has c<strong>on</strong>siderableclinical expertise in treating <strong>patient</strong>s with GVHD. The clinic staff, including Estil Vance, MD,medical <strong>on</strong>cologist and Jennifer Ca<strong>the</strong>r, MD, dermatologist, both <strong>on</strong> <strong>the</strong> medical staff at<strong>Baylor</strong> Dallas, is highly specialized and has c<strong>on</strong>siderable clinical expertise in treating<strong>patient</strong>s with GVHD.Update <strong>on</strong> <strong>the</strong> Apheresis Unit: Novel Researchby Luis Piñeiro, MDDr. Luis PiñeiroThe apheresis unit at <strong>Baylor</strong> Samm<strong>on</strong>s Cancer Center c<strong>on</strong>tinues to play an important supportingrole to <strong>the</strong> Blood and Marrow Transplant Program. It collected approximately 500stem cell products in 2007. These products were utilized for autologous and allogeneictransplants. Thirteen of <strong>the</strong>se products were collected from d<strong>on</strong>ors of <strong>the</strong> Nati<strong>on</strong>al MarrowD<strong>on</strong>or Program, for which <strong>Baylor</strong> serves as a collecti<strong>on</strong> center. In additi<strong>on</strong>, <strong>the</strong> unitperformed nearly 600 extracorporeal photopheresis procedures for <strong>the</strong> treatment of graftversus-hostdisease (GVHD).
<str<strong>on</strong>g>Focused</str<strong>on</strong>g> <strong>on</strong> specialized care 13The apheresis unit also performs procedures for <strong>patient</strong>s at <strong>Baylor</strong> University MedicalCenter. These c<strong>on</strong>sisted of plasma exchanges, leukopheresis, platelet-pheresis, and red cellexchanges. These procedures are c<strong>on</strong>sidered essential treatment for a variety of disordersin different fields of medicine: neurology, nephrology, hematology, and rheumatology, inadditi<strong>on</strong> to solid organ transplantati<strong>on</strong>.The unit is involved instudies exploring noveluses of adult stem cellsfor tissue repair.Collaborati<strong>on</strong> in research studies c<strong>on</strong>tinues to be a priority for <strong>the</strong> apheresis unit as wellas <strong>the</strong> marrow processing laboratories. Stem cells have been collected for <strong>the</strong> study ofdendritic cells in normal volunteers, as well as for research studies of dendritic cells for <strong>the</strong>Amanda SwinkAmanda Swink has cause for celebrati<strong>on</strong>: she recently reached<strong>the</strong> 1-year anniversary of a new, life-saving procedure. In 2006,23-year-old Amanda became <strong>the</strong> recipient of <strong>the</strong> first successfulcord blood transplant at <strong>Baylor</strong> University Medical Center atDallas. From birth, Amanda had a rare disorder called severecyclic neutropenia, which later degenerated into leukemia.Luckily, 6 years earlier a mo<strong>the</strong>r of a newborn boy voluntarilyd<strong>on</strong>ated her s<strong>on</strong>’s cord blood to a volunteer cord blood bank.This made <strong>the</strong> cord blood available to any pers<strong>on</strong> who mightneed it to treat cancer. Registry search experts at <strong>Baylor</strong> Dallasidentified <strong>the</strong> cord from this infant as a potential perfect matchfor Amanda.Amanda Swink and stepdaughter, Deanna, enjoying a Springday at <strong>the</strong> park.Amanda was hospitalized and prepared for transplantati<strong>on</strong>with chemo<strong>the</strong>rapy and radiati<strong>on</strong>. The cord blood unit wasflown by courier to <strong>Baylor</strong> Dallas where Amanda received itas a transfusi<strong>on</strong>. A year later, Amanda’s leukemia remains inremissi<strong>on</strong>, and she is enjoying a happy, productive and normallife.Stories such as Amanda Swink’s give us hope that <strong>the</strong> future of leukemia and cancers of <strong>the</strong> blood will so<strong>on</strong> be treated withsimple and easy-to-tolerate treatments. Innovati<strong>on</strong> and research remain <strong>the</strong> cornerst<strong>on</strong>es in <strong>the</strong> field or transplantati<strong>on</strong>.Improvements in survival and outcome are made daily. In fact, statistically <strong>the</strong> survival of <strong>patient</strong>s undergoing transplantati<strong>on</strong>has improved nati<strong>on</strong>ally, year by year, over <strong>the</strong> past decade. Such improvement gives hope that <strong>patient</strong>s may c<strong>on</strong>tinueto enjoy a quality of life that is superior to that of a <strong>patient</strong> undergoing cancer treatment.It is toward this end that <strong>the</strong> research team and program c<strong>on</strong>tinue to fund developed research activities and present <strong>the</strong>irdata at nati<strong>on</strong>al meetings. We c<strong>on</strong>tinue to strive for excellence in clinical and compassi<strong>on</strong>ate care.